Last update Oct. 5, 2023

Dihydroergocristine Mesilate

Very High Risk

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Comment.

Ergot alkaloid with dopaminergic effect used as a peripheral vasodilator in cerebral vascular insufficiency, mental deterioration and vertiginous syndrome. Oral, intramuscular or intravenous administration. 

At the date of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very large volume of distribution and moderately high molecular weight) make it unlikely to pass into breast milk in clinically significant quantities.

As a dopaminergic agonist, it inhibits prolactin and suppresses lactation. (Aloysio 1988)

It is a non-essential medication, of low therapeutic level (SEFAP 2012, INSALUD 2001), with frequent and important side effects; perfectly dispensable.


See below the information of this related product:

  • Ergot Fungus (Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Comment.)

Alternatives

We do not have alternatives for Dihydroergocristine Mesilate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dihydroergocristine Mesilate in other languages or writings:

  • メシル酸ジヒドロエルゴクリスチン (Japanese)
  • (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-isopropyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulphonate (Chemical name)
  • C35H41N5O5,CH4O3S (Molecular formula)
  • C04AE04 (ATC Code/s)

Group

Dihydroergocristine Mesilate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Dihydroergocristine Mesilate in its composition:

  • Brinerdina
  • Cervilan™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Cervilane™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Clinadil™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Decme
  • Diemil™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Diertine
  • Ergodavur
  • Iskemil
  • Isketam™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Metadiemil™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Micerfin™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Norogil™. Contains other elements than Dihydroergocristine Mesilate in its composition
  • Vertizine D™. Contains other elements than Dihydroergocristine Mesilate in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. < 25 %
Molecular weight 708 daltons
Protein Binding 68 %
VD 52 l/Kg
pKa 9.71 -
Tmax 0.46 ± 0.26 hours
3.5 ± 2.27 hours

References

  1. AEMPS. Dihidroergocristina (Dertine). Ficha técnica. 2021 Full text (in our servers)
  2. PharmaDorf. Cervilane. Prospecto. 2020 Full text (in our servers)
  3. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract
  4. SEFAP. Sociedad Española de Farmacéuticos de Atención Primaria. Propuesta de medicamentos a desfinanciar por el Sistema Nacional de Salud. . 2012 Full text (in our servers)
  5. INSALUD. Área de Gestión de Farmacia. Subdirección General de Atención Primaria. Instituto Nacional de la Salud. Utilidad terapéutica de los medicamentos financiados por el Sistema Nacional de Salud. . 2001 Full text (in our servers)
  6. de Aloysio D, Pamparana F, Zanotti A, Fabiani AG, Bottiglioni F. Dihydroergocristine in stopping lactation: double-blind study vs bromocriptine. Gynecol Endocrinol. 1988 Mar;2(1):67-71. Abstract

Total visits

6,305

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM